Tag: ASX: CAN
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Featured Article
Australian Manufacturing Week 2026 enters final run-up to Brisbane debut
Australia’s manufacturing sector continues to play a critical role in the national economy, underpinned by ongoing investment in advanced technologies, automation, and high-value production.
